The Treatment of Chronic Depression, Part 3
Ivan W. Miller(Rhode Island Hospital), Martin B. Keller, Daniel N. Klein(Stony Brook University), Wilma Harrison(Pfizer (United States)), Alan F. Schatzberg(Stanford University), Susan G. Kornstein(Virginia Commonwealth University), David Schlager(Stony Brook University), Michael E. Thase(Veterans Health Administration), Sonia M. Davis(University of North Carolina at Chapel Hill), Gabor I. Keitner(Brown University), John C. Markowitz(New York Psychoanalytic Society and Institute), A. John Rush(The University of Texas Southwestern Medical Center)
Cited by 306
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Resting-state connectivity biomarkers define neurophysiological subtypes of depression
|Nature Medicine|2016|2.2k
Major depressive disorder
|Nature Reviews Disease Primers|2016|2.1k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
|Controlled Clinical Trials|2004|1.1k